[S02DA03, antipyrine, The serum concentration of Antipyrine can be decreased when it is combined with Leflunomide.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leflunomide.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Leflunomide.]
[L04AA27, fingolimod, Leflunomide may increase the immunosuppressive activities of Fingolimod.]
[J01EC02, sulfadiazine, The metabolism of Leflunomide can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Leflunomide can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Leflunomide.]
[J01EC03, sulfamoxole, The metabolism of Leflunomide can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Leflunomide can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Leflunomide can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Leflunomide can be decreased when combined with Sulfisoxazole.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Leflunomide.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Leflunomide.]
[N06DA01, tacrine, The serum concentration of Tacrine can be decreased when it is combined with Leflunomide.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be decreased when it is combined with Leflunomide.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Leflunomide.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Leflunomide.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Leflunomide.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Leflunomide.]
[R03DA07, theobromine, The serum concentration of Theobromine can be decreased when it is combined with Leflunomide.]
[R03DA04, theophylline, The serum concentration of Theophylline can be decreased when it is combined with Leflunomide.]
[P02CA02, thiabendazole, The serum concentration of Thiabendazole can be decreased when it is combined with Leflunomide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Leflunomide.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Leflunomide.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Leflunomide.]
[N05AF04, thiothixene, The serum concentration of Thiothixene can be decreased when it is combined with Leflunomide.]
[B01AC05, ticlopidine, The metabolism of Leflunomide can be decreased when combined with Ticlopidine.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Leflunomide.]
[V04CA01, tolbutamide, The serum concentration of Tolbutamide can be increased when it is combined with Leflunomide.]
[N06AF04, tranylcypromine, The metabolism of Leflunomide can be decreased when combined with Tranylcypromine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Leflunomide.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Leflunomide.]
[C03DB02, triamterene, The serum concentration of Triamterene can be decreased when it is combined with Leflunomide.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Leflunomide.]
[N05AB06, trifluoperazine, The serum concentration of Trifluoperazine can be decreased when it is combined with Leflunomide.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Leflunomide.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Fluclorolone is combined with Leflunomide.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Leflunomide.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Leflunomide.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Leflunomide.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Leflunomide.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Leflunomide.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Leflunomide.]
[L01EX04, vandetanib, Vandetanib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Leflunomide can be increased when it is combined with Abiraterone.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Leflunomide.]
[B01AC24, ticagrelor, The metabolism of Leflunomide can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Verapamil can be decreased when it is combined with Leflunomide.]
[N06AX09, viloxazine, The metabolism of Leflunomide can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Leflunomide.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Leflunomide.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Leflunomide.]
[B01AA03, warfarin, The serum concentration of Warfarin can be decreased when it is combined with Leflunomide.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Leflunomide.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Leflunomide.]
[L01EC01, vemurafenib, The serum concentration of Leflunomide can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Leflunomide.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Leflunomide.]
[R03DC01, zafirlukast, The metabolism of Leflunomide can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Leflunomide.]
[J01MA13, trovafloxacin, The metabolism of Leflunomide can be decreased when combined with Trovafloxacin.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leflunomide.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Leflunomide.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Leflunomide.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Leflunomide.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Leflunomide.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Leflunomide.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be decreased when combined with Leflunomide.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01EK01, axitinib, The serum concentration of Axitinib can be decreased when it is combined with Leflunomide.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Prednylidene is combined with Leflunomide.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Leflunomide.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Leflunomide.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Leflunomide.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Leflunomide.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Leflunomide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide.]
[A08AA11, lorcaserin, The serum concentration of Lorcaserin can be decreased when it is combined with Leflunomide.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carfilzomib is combined with Leflunomide.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L02BB04, enzalutamide, The serum concentration of Leflunomide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Bosutinib is combined with Leflunomide.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Leflunomide is combined with Teriflunomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Leflunomide.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Leflunomide.]
[L01EX05, regorafenib, Regorafenib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Leflunomide.]
[N04BD02, rasagiline, The serum concentration of Rasagiline can be decreased when it is combined with Leflunomide.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Leflunomide.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Leflunomide.]
[N03AX22, perampanel, The serum concentration of Perampanel can be decreased when it is combined with Leflunomide.]
[L04AA29, tofacitinib, The risk or severity of adverse effects can be increased when Tofacitinib is combined with Leflunomide.]
[N02CC03, zolmitriptan, The serum concentration of Zolmitriptan can be decreased when it is combined with Leflunomide.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Leflunomide.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Leflunomide.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Ponatinib is combined with Leflunomide.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Leflunomide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Leflunomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Leflunomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Leflunomide.]
[J01MA15, gemifloxacin, The metabolism of Leflunomide can be decreased when combined with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Leflunomide can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The metabolism of Leflunomide can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Leflunomide can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The serum concentration of Benzocaine can be decreased when it is combined with Leflunomide.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Leflunomide.]
[C10AC04, colesevelam, Colesevelam may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Everolimus is combined with Leflunomide.]
[L01EC02, dabrafenib, The serum concentration of Leflunomide can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The serum concentration of Benzyl alcohol can be decreased when it is combined with Leflunomide.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Leflunomide.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Leflunomide.]
[J05AP05, simeprevir, The metabolism of Leflunomide can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The serum concentration of Dapagliflozin can be decreased when it is combined with Leflunomide.]
[N05CH03, tasimelteon, The serum concentration of Tasimelteon can be decreased when it is combined with Leflunomide.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Apremilast is combined with Leflunomide.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Leflunomide.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be decreased when it is combined with Leflunomide.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Bezafibrate.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Leflunomide.]
[L01ED02, ceritinib, The metabolism of Leflunomide can be decreased when combined with Ceritinib.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Leflunomide.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be decreased when it is combined with Leflunomide.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Leflunomide.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Idelalisib is combined with Leflunomide.]
[N07XX08, tafamidis, The serum concentration of Leflunomide can be increased when it is combined with Tafamidis.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Leflunomide.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Leflunomide.]
[J01XA05, oritavancin, The metabolism of Leflunomide can be decreased when combined with Oritavancin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Leflunomide.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Leflunomide.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Leflunomide.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Olaparib is combined with Leflunomide.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Leflunomide.]
[N06AX11, mirtazapine, The serum concentration of Mirtazapine can be decreased when it is combined with Leflunomide.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Leflunomide.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Leflunomide.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Panobinostat is combined with Leflunomide.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N02BE01, acetaminophen, The serum concentration of Acetaminophen can be decreased when it is combined with Leflunomide.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Leflunomide.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Leflunomide.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Leflunomide.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Acipimox.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Leflunomide.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Leflunomide.]
[J02AC05, isavuconazole, Isavuconazole may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01EB04, osimertinib, The serum concentration of Leflunomide can be decreased when it is combined with Osimertinib.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Leflunomide.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Leflunomide.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Leflunomide.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ixekizumab is combined with Leflunomide.]
[L01XX52, venetoclax, Venetoclax may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N05BA08, bromazepam, The serum concentration of Bromazepam can be decreased when it is combined with Leflunomide.]
[A05AA04, obeticholic acid, The metabolism of Leflunomide can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Leflunomide.]
[N01BB01, bupivacaine, The serum concentration of Levobupivacaine can be decreased when it is combined with Leflunomide.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Leflunomide.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Leflunomide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Leflunomide.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[S01GX07, azelastine, The serum concentration of Azelastine can be decreased when it is combined with Leflunomide.]
[L01XK03, rucaparib, The serum concentration of Rucaparib can be decreased when it is combined with Leflunomide.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Brodalumab is combined with Leflunomide.]
[R03DA08, bamifylline, The serum concentration of Bamifylline can be decreased when it is combined with Leflunomide.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Leflunomide.]
[N06BC01, caffeine, The serum concentration of Caffeine can be decreased when it is combined with Leflunomide.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Leflunomide.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Leflunomide.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.]
[L01ED04, brigatinib, Brigatinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Leflunomide.]
[J01MA23, delafloxacin, The metabolism of Leflunomide can be increased when combined with Delafloxacin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Guselkumab is combined with Leflunomide.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Leflunomide.]
[L01XX59, enasidenib, The serum concentration of Enasidenib can be decreased when it is combined with Leflunomide.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Leflunomide.]
[L01EF03, abemaciclib, Abemaciclib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[J05AG03, efavirenz, The serum concentration of Efavirenz can be decreased when it is combined with Leflunomide.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Leflunomide.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Leflunomide.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Leflunomide.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N01BX04, capsaicin, The serum concentration of Capsaicin can be decreased when it is combined with Leflunomide.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Captopril.]
[L02BB05, apalutamide, Apalutamide may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Leflunomide.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Leflunomide.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Leflunomide.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be decreased when it is combined with Leflunomide.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Baricitinib is combined with Leflunomide.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be decreased when it is combined with Leflunomide.]
[L01XX62, ivosidenib, The metabolism of Leflunomide can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The excretion of Leflunomide can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Leflunomide.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Leflunomide.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Leflunomide.]
[R03DA02, oxtriphylline, The serum concentration of Oxtriphylline can be decreased when it is combined with Leflunomide.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Emapalumab is combined with Leflunomide.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Leflunomide.]
[L01EX13, gilteritinib, Gilteritinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ravulizumab is combined with Leflunomide.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be decreased when it is combined with Leflunomide.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Ciprofibrate.]
[P02BX04, triclabendazole, The serum concentration of Triclabendazole can be decreased when it is combined with Leflunomide.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Leflunomide.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Siponimod is combined with Leflunomide.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Leflunomide.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Cloprednol is combined with Leflunomide.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Ubidecarenone.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Leflunomide.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Leflunomide.]
[V03AE02, sevelamer, Sevelamer may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Cortivazol is combined with Leflunomide.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Risankizumab is combined with Leflunomide.]
[L01EM03, alpelisib, The serum concentration of Leflunomide can be decreased when it is combined with Alpelisib.]
[L02BB06, darolutamide, The serum concentration of Leflunomide can be increased when it is combined with Darolutamide.]
[M03BX08, cyclobenzaprine, The serum concentration of Cyclobenzaprine can be decreased when it is combined with Leflunomide.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Upadacitinib is combined with Leflunomide.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N07XX11, pitolisant, The metabolism of Leflunomide can be increased when combined with Pitolisant.]
[N04CX01, istradefylline, The serum concentration of Istradefylline can be decreased when it is combined with Leflunomide.]
[A10AE03, insulin, regular, pork, The metabolism of Leflunomide can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Leflunomide.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Deflazacort is combined with Leflunomide.]
[L01FD01, trastuzumab, The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leflunomide.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Leflunomide.]
[N02CC08, lasmiditan, The serum concentration of Leflunomide can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Diroximel fumarate is combined with Leflunomide.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Leflunomide.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Leflunomide.]
[A16AX16, givosiran, The serum concentration of Leflunomide can be increased when it is combined with Givosiran.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Leflunomide.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Leflunomide.]
[M01AX21, diacetylrhein, The metabolism of Leflunomide can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Leflunomide can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Leflunomide can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Leflunomide.]
[N02CC07, frovatriptan, The serum concentration of Frovatriptan can be decreased when it is combined with Leflunomide.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Ozanimod is combined with Leflunomide.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be decreased when it is combined with Leflunomide.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Leflunomide.]
[M01AH02, rofecoxib, The serum concentration of Rofecoxib can be decreased when it is combined with Leflunomide.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Leflunomide.]
[C08CA16, clevidipine, The metabolism of Leflunomide can be decreased when combined with Clevidipine.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Leflunomide.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Leflunomide.]
[L01EX17, capmatinib, The serum concentration of Leflunomide can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Leflunomide.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Leflunomide is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Leflunomide.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Leflunomide.]
[L04AC19, satralizumab, The serum concentration of Leflunomide can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Leflunomide.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N05AA01, chlorpromazine, The serum concentration of Chlorpromazine can be decreased when it is combined with Leflunomide.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Leflunomide.]
[M03BB03, chlorzoxazone, The serum concentration of Chlorzoxazone can be decreased when it is combined with Leflunomide.]
[C10AC01, cholestyramine resin, Cholestyramine may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Leflunomide.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Etofibrate.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Leflunomide.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Leflunomide.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Voclosporin is combined with Leflunomide.]
[P03AX07, abametapir, The serum concentration of Leflunomide can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Leflunomide can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, The metabolism of Leflunomide can be increased when combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Leflunomide can be decreased when combined with Felbamate.]
[N06BA10, fenethylline, The serum concentration of Fenethylline can be decreased when it is combined with Leflunomide.]
[J01MB07, flumequine, The metabolism of Leflunomide can be decreased when combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Leflunomide.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Leflunomide.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Ponesimod is combined with Leflunomide.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Leflunomide.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Leflunomide.]
[N07CA02, cinnarizine, The serum concentration of Cinnarizine can be decreased when it is combined with Leflunomide.]
[J01MB06, cinoxacin, The metabolism of Leflunomide can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Leflunomide can be increased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Leflunomide can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide.]
[N06AB04, citalopram, The metabolism of Leflunomide can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Pegcetacoplan is combined with Leflunomide.]
[H01AC07, somapacitan, The metabolism of Leflunomide can be increased when combined with Somapacitan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Belumosudil is combined with Leflunomide.]
[P01CA03, fexinidazole, The serum concentration of Fexinidazole can be decreased when it is combined with Leflunomide.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Anifrolumab is combined with Leflunomide.]
[H01AC09, lonapegsomatropin, The metabolism of Leflunomide can be increased when combined with Lonapegsomatropin.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Leflunomide.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Leflunomide.]
[L01EA06, asciminib, The metabolism of Leflunomide can be decreased when combined with Asciminib.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Ropeginterferon alfa-2b is combined with Leflunomide.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Leflunomide.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Leflunomide.]
[N01BB10, levobupivacaine, The serum concentration of Levobupivacaine can be decreased when it is combined with Leflunomide.]
[L01EJ03, pacritinib, The serum concentration of Leflunomide can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be decreased when it is combined with Leflunomide.]
[S01EA04, clonidine, The serum concentration of Clonidine can be decreased when it is combined with Leflunomide.]
[C01EB24, mavacamten, The serum concentration of Leflunomide can be decreased when it is combined with Mavacamten.]
[J02AC06, oteseconazole, The serum concentration of Leflunomide can be increased when it is combined with Oteseconazole.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Spesolimab is combined with Leflunomide.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Deucravacitinib is combined with Leflunomide.]
[A04AA01, ondansetron, The serum concentration of Ondansetron can be decreased when it is combined with Leflunomide.]
[N05AH02, clozapine, The serum concentration of Clozapine can be decreased when it is combined with Leflunomide.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Leflunomide can be increased when combined with Somatrogon.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Bimekizumab is combined with Leflunomide.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Colchicine.]
[C10AC02, colestipol, Colestipol may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Leflunomide.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[J01MB04, pipemidic acid, The metabolism of Leflunomide can be decreased when combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Leflunomide.]
[M01AG01, mefenamic acid, The serum concentration of Mefenamic acid can be decreased when it is combined with Leflunomide.]
[A07BA01, activated charcoal, Activated charcoal can cause a decrease in the absorption of Leflunomide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Leflunomide.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Leflunomide.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Leflunomide.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Leflunomide.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[S01AD03, acyclovir, The serum concentration of Acyclovir can be decreased when it is combined with Leflunomide.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Leflunomide.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Leflunomide.]
[N07BC04, lofexidine, The serum concentration of Lofexidine can be decreased when it is combined with Leflunomide.]
[S01AE04, lomefloxacin, The serum concentration of Lomefloxacin can be decreased when it is combined with Leflunomide.]
[C08CA11, manidipine, The metabolism of Leflunomide can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Mebeverine.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Meprednisone is combined with Leflunomide.]
[R06AE03, cyclizine, The metabolism of Leflunomide can be decreased when combined with Cyclizine.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Leflunomide.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Leflunomide.]
[S01XA18, cyclosporine, Leflunomide may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Leflunomide can be decreased when combined with Modafinil.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be increased when it is combined with Leflunomide.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Leflunomide.]
[J05AF10, entecavir, The serum concentration of Entecavir can be decreased when it is combined with Leflunomide.]
[M01AH05, etoricoxib, The serum concentration of Etoricoxib can be decreased when it is combined with Leflunomide.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Leflunomide.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Leflunomide.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Leflunomide.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Leflunomide.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Leflunomide.]
[M01AX01, nabumetone, The serum concentration of Nabumetone can be decreased when it is combined with Leflunomide.]
[L02BB02, nilutamide, The metabolism of Leflunomide can be decreased when combined with Nilutamide.]
[C01CA23, theodrenaline, The serum concentration of Theodrenaline can be decreased when it is combined with Leflunomide.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Leflunomide.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Leflunomide.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Leflunomide.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide.]
[A08AA04, dexfenfluramine, The serum concentration of Dexfenfluramine can be decreased when it is combined with Leflunomide.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Leflunomide.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Leflunomide.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Leflunomide.]
[B01AC04, clopidogrel, The serum concentration of Clopidogrel can be decreased when it is combined with Leflunomide.]
[C04AD01, pentifylline, The serum concentration of Pentifylline can be decreased when it is combined with Leflunomide.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Leflunomide.]
[S01BC03, diclofenac, The serum concentration of Diclofenac can be decreased when it is combined with Leflunomide.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Ixabepilone is combined with Leflunomide.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Leflunomide.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Pirarubicin is combined with Leflunomide.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Leflunomide.]
[C02DB01, dihydralazine, The serum concentration of Dihydralazine can be decreased when it is combined with Leflunomide.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Leflunomide.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Leflunomide.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Leflunomide.]
[J05AE08, atazanavir, The metabolism of Leflunomide can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Leflunomide.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Leflunomide.]
[N06BC02, propentofylline, The serum concentration of Propentofylline can be decreased when it is combined with Leflunomide.]
[C05CA03, diosmin, The metabolism of Leflunomide can be decreased when combined with Diosmin.]
[R03DA03, proxyphylline, The serum concentration of Proxyphylline can be decreased when it is combined with Leflunomide.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Leflunomide.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Leflunomide.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Leflunomide.]
[C01BA03, disopyramide, The serum concentration of Disopyramide can be decreased when it is combined with Leflunomide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Leflunomide is combined with Natalizumab.]
[S02AA12, rifamycin SV, The metabolism of Leflunomide can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The serum concentration of Riluzole can be decreased when it is combined with Leflunomide.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Leflunomide.]
[N01BB09, ropivacaine, The serum concentration of Ropivacaine can be decreased when it is combined with Leflunomide.]
[J01MB01, rosoxacin, The metabolism of Leflunomide can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Leflunomide.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Leflunomide.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Leflunomide.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Leflunomide.]
[A03FA03, domperidone, The serum concentration of Domperidone can be decreased when it is combined with Leflunomide.]
[N06AA16, dothiepin, The metabolism of Leflunomide can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The serum concentration of Doxepin can be decreased when it is combined with Leflunomide.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Leflunomide.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Leflunomide.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Leflunomide.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Leflunomide.]
[J01MA05, temafloxacin, The serum concentration of Temafloxacin can be decreased when it is combined with Leflunomide.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Leflunomide.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Leflunomide.]
[D01BA02, terbinafine, The serum concentration of Terbinafine can be decreased when it is combined with Leflunomide.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Leflunomide.]
[C03CA04, torsemide, The metabolism of Leflunomide can be decreased when combined with Torasemide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Leflunomide.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Trofosfamide is combined with Leflunomide.]
[J01MA04, enoxacin, The metabolism of Leflunomide can be decreased when combined with Enoxacin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Leflunomide.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA01, epinephrine, The metabolism of Leflunomide can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Leflunomide.]
[N05CF02, zolpidem, The serum concentration of Zolpidem can be decreased when it is combined with Leflunomide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Leflunomide.]
[N05AX11, zotepine, The serum concentration of Zotepine can be decreased when it is combined with Leflunomide.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Leflunomide.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Iloprost is combined with Leflunomide.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[H05BX01, cinacalcet, The serum concentration of Cinacalcet can be decreased when it is combined with Leflunomide.]
[G03CA03, estradiol, The serum concentration of Estradiol can be decreased when it is combined with Leflunomide.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Leflunomide.]
[G03CA57, estrogens, conjugated (USP), The serum concentration of Conjugated estrogens can be decreased when it is combined with Leflunomide.]
[J04AK02, ethambutol, The metabolism of Leflunomide can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Leflunomide.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Fluticasone is combined with Leflunomide.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fluvastatin is combined with Leflunomide.]
[L02AA03, ethinyl estradiol, The serum concentration of Ethinylestradiol can be decreased when it is combined with Leflunomide.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Leflunomide.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Leflunomide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Leflunomide.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Leflunomide.]
[N06AX12, bupropion, The metabolism of Bupropion can be decreased when combined with Leflunomide.]
[N06AB08, fluvoxamine, The serum concentration of Fluvoxamine can be decreased when it is combined with Leflunomide.]
[C01BB03, tocainide, The serum concentration of Tocainide can be decreased when it is combined with Leflunomide.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Leflunomide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Leflunomide.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Leflunomide.]
[A02BA03, famotidine, The metabolism of Leflunomide can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The serum concentration of Albendazole can be decreased when it is combined with Leflunomide.]
[C08CA02, felodipine, The metabolism of Leflunomide can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The serum concentration of Fenfluramine can be decreased when it is combined with Leflunomide.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Leflunomide.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Leflunomide.]
[C01BC04, flecainide, The serum concentration of Flecainide can be decreased when it is combined with Leflunomide.]
[J02AC01, fluconazole, The metabolism of Leflunomide can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Leflunomide.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Leflunomide.]
[D07XB01, flumethasone, The risk or severity of adverse effects can be increased when Flumethasone is combined with Leflunomide.]
[N07CA03, flunarizine, The serum concentration of Flunarizine can be decreased when it is combined with Leflunomide.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Leflunomide.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Leflunomide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Leflunomide.]
[V03AZ01, ethanol, The serum concentration of Ethanol can be decreased when it is combined with Leflunomide.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Leflunomide.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Leflunomide.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Leflunomide.]
[N06AB03, fluoxetine, The serum concentration of Fluoxetine can be decreased when it is combined with Leflunomide.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Leflunomide.]
[L02BB01, flutamide, The serum concentration of Flutamide can be decreased when it is combined with Leflunomide.]
[L01BC03, tegafur, The serum concentration of Tegafur can be decreased when it is combined with Leflunomide.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ganciclovir is combined with Leflunomide.]
[C10AB04, gemfibrozil, The metabolism of Leflunomide can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Leflunomide.]
[C01CA21, cafedrine, The serum concentration of Cafedrine can be decreased when it is combined with Leflunomide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Leflunomide.]
[A10BB01, glyburide, The metabolism of Leflunomide can be decreased when combined with Glyburide.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Leflunomide.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Leflunomide.]
[N05CM18, dexmedetomidine, The metabolism of Leflunomide can be decreased when combined with Dexmedetomidine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Leflunomide.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Leflunomide.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Leflunomide.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be decreased when it is combined with Leflunomide.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Leflunomide.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Leflunomide.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Leflunomide.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Leflunomide.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Leflunomide.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Leflunomide.]
[S02BA01, hydrocortisone, The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Leflunomide.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Leflunomide.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Leflunomide.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Leflunomide.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Leflunomide.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Leflunomide.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Leflunomide.]
[H01AC02, somatrem, The metabolism of Leflunomide can be increased when combined with Somatrem.]
[N06AA02, imipramine, The serum concentration of Imipramine can be decreased when it is combined with Leflunomide.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Tixocortol is combined with Leflunomide.]
[M03BX02, tizanidine, The serum concentration of Tizanidine can be decreased when it is combined with Leflunomide.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Leflunomide.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Leflunomide.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Leflunomide.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Leflunomide.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Leflunomide.]
[N05CH02, ramelteon, The serum concentration of Ramelteon can be decreased when it is combined with Leflunomide.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Leflunomide.]
[L01XX35, anagrelide, The serum concentration of Anagrelide can be decreased when it is combined with Leflunomide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Leflunomide.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Leflunomide.]
[N06AF05, iproniazid, The metabolism of Leflunomide can be decreased when combined with Iproniazid.]
[J05AB13, penciclovir, The serum concentration of Penciclovir can be decreased when it is combined with Leflunomide.]
[P01AX06, atovaquone, The metabolism of Leflunomide can be decreased when combined with Atovaquone.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Leflunomide.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Leflunomide.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Leflunomide.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Leflunomide.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Leflunomide.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Leflunomide.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Leflunomide.]
[J02AB02, ketoconazole, The metabolism of Leflunomide can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The serum concentration of Olanzapine can be decreased when it is combined with Leflunomide.]
[V03AC03, deferasirox, The serum concentration of Leflunomide can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Leflunomide.]
[J01MB02, nalidixic acid, The metabolism of Leflunomide can be decreased when combined with Nalidixic acid.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Leflunomide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Leflunomide.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be decreased when it is combined with Leflunomide.]
[N06BA13, armodafinil, The metabolism of Leflunomide can be increased when combined with Armodafinil.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Leflunomide.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Leflunomide.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Leflunomide.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Temsirolimus is combined with Leflunomide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Leflunomide.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Nilotinib is combined with Leflunomide.]
[N06AA21, maprotiline, The serum concentration of Maprotiline can be decreased when it is combined with Leflunomide.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Leflunomide.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Leflunomide.]
[N05CH01, melatonin, The serum concentration of Melatonin can be decreased when it is combined with Leflunomide.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Leflunomide.]
[N03AB04, mephenytoin, The serum concentration of Mephenytoin can be decreased when it is combined with Leflunomide.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Leflunomide.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Leflunomide.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Leflunomide.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Leflunomide.]
[D05BA02, methoxsalen, The metabolism of Leflunomide can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Leflunomide.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Leflunomide.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be decreased when it is combined with Leflunomide.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be decreased when it is combined with Leflunomide.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Leflunomide.]
[A03FA01, metoclopramide, The serum concentration of Metoclopramide can be decreased when it is combined with Leflunomide.]
[P01AB01, metronidazole, The metabolism of Leflunomide can be decreased when combined with Metronidazole.]
[C01BB02, mexiletine, The serum concentration of Mexiletine can be decreased when it is combined with Leflunomide.]
[N06AX03, mianserin, The serum concentration of Mianserin can be decreased when it is combined with Leflunomide.]
[S02AA13, miconazole, The metabolism of Leflunomide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The serum concentration of Aminophenazone can be decreased when it is combined with Leflunomide.]
[G03XB01, mifepristone, The metabolism of Leflunomide can be decreased when combined with Mifepristone.]
[C09CA03, valsartan, The metabolism of Leflunomide can be decreased when combined with Valsartan.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Minocycline is combined with Leflunomide.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Leflunomide.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Leflunomide.]
[C01BD01, amiodarone, The metabolism of Leflunomide can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The serum concentration of Amitriptyline can be decreased when it is combined with Leflunomide.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Leflunomide.]
[B02BX05, eltrombopag, The serum concentration of Eltrombopag can be decreased when it is combined with Leflunomide.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Leflunomide.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Pazopanib is combined with Leflunomide.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Leflunomide.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Raltegravir.]
[P01BA06, amodiaquine, The metabolism of Leflunomide can be decreased when combined with Amodiaquine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Leflunomide.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Leflunomide.]
[N04BC04, ropinirole, The serum concentration of Ropinirole can be decreased when it is combined with Leflunomide.]
[J01CF06, nafcillin, The metabolism of Leflunomide can be increased when combined with Nafcillin.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Leflunomide.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Leflunomide.]
[M02AA12, naproxen, The serum concentration of Naproxen can be decreased when it is combined with Leflunomide.]
[A10BG01, troglitazone, The metabolism of Leflunomide can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Leflunomide.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Docetaxel is combined with Leflunomide.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Leflunomide.]
[A10BX02, repaglinide, The serum concentration of Repaglinide can be increased when it is combined with Leflunomide.]
[J02AA01, amphotericin B, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Leflunomide.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Leflunomide can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Leflunomide.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Leflunomide.]
[C08CA04, nicardipine, The metabolism of Leflunomide can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Leflunomide can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be decreased when it is combined with Leflunomide.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Norfloxacin is combined with Leflunomide.]
[C02KX01, bosentan, The metabolism of Leflunomide can be increased when combined with Bosentan.]
[R05DA07, noscapine, The metabolism of Leflunomide can be decreased when combined with Noscapine.]
[L03AB07, interferon beta-1a, The metabolism of Leflunomide can be decreased when combined with Interferon beta-1a.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Ofloxacin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Rilonacept is combined with Leflunomide.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[A14AA08, oxandrolone, The metabolism of Leflunomide can be decreased when combined with Oxandrolone.]
[N05AH05, asenapine, The serum concentration of Asenapine can be decreased when it is combined with Leflunomide.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Leflunomide.]
[J01MA03, pefloxacin, The metabolism of Leflunomide can be decreased when combined with Pefloxacin.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Leflunomide.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Leflunomide.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Leflunomide.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Leflunomide.]
[C04AD03, pentoxifylline, The serum concentration of Pentoxifylline can be decreased when it is combined with Leflunomide.]
[N05AB03, perphenazine, The serum concentration of Perphenazine can be decreased when it is combined with Leflunomide.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Leflunomide.]
[N02BE03, phenacetin, The serum concentration of Phenacetin can be decreased when it is combined with Leflunomide.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Leflunomide.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Leflunomide.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Leflunomide.]
[M02AA01, phenylbutazone, The metabolism of Leflunomide can be decreased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Leflunomide can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Leflunomide.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Leflunomide.]
[C08CX01, mibefradil, The metabolism of Leflunomide can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The serum concentration of Pimozide can be decreased when it is combined with Leflunomide.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Atorvastatin is combined with Leflunomide.]
[J05AE01, saquinavir, Saquinavir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Leflunomide.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Leflunomide.]
[J01MA11, grepafloxacin, The serum concentration of Grepafloxacin can be decreased when it is combined with Leflunomide.]
[J05AG02, delavirdine, The metabolism of Leflunomide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Leflunomide.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Leflunomide.]
[A03AE01, alosetron, The serum concentration of Alosetron can be decreased when it is combined with Leflunomide.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Leflunomide.]
[J05AE03, ritonavir, Ritonavir may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leflunomide is combined with Pitavastatin.]
[P02BA01, praziquantel, The serum concentration of Praziquantel can be decreased when it is combined with Leflunomide.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Leflunomide.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Leflunomide.]
[P01BA03, primaquine, The serum concentration of Primaquine can be decreased when it is combined with Leflunomide.]
[N03AA03, primidone, The metabolism of Leflunomide can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Leflunomide can be decreased when combined with Probenecid.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procainamide is combined with Leflunomide.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Leflunomide.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Leflunomide.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N05AA03, promazine, The serum concentration of Promazine can be decreased when it is combined with Leflunomide.]
[R06AD02, promethazine, The metabolism of Leflunomide can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The serum concentration of Propafenone can be decreased when it is combined with Leflunomide.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Leflunomide.]
[C07AA05, propranolol, The serum concentration of Propranolol can be decreased when it is combined with Leflunomide.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Leflunomide.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Leflunomide.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Leflunomide.]
[C01BA01, quinidine, The metabolism of Leflunomide can be decreased when combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Quinine can be decreased when it is combined with Leflunomide.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be decreased when it is combined with Leflunomide.]
[J04AB02, rifampin, The serum concentration of teriflunomide (A77 1726), an active metabolite of Leflunomide, can be increased when used in combination with Rifampicin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Leflunomide.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Leflunomide.]
[N04BD01, selegiline, The serum concentration of Selegiline can be decreased when it is combined with Leflunomide.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Leflunomide.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Leflunomide.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leflunomide.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Leflunomide.]
[N03AG01, valproic acid, The metabolism of Leflunomide can be decreased when combined with Valproic acid.]
[M05BA04, alendronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Leflunomide.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Leflunomide.]
